Literature DB >> 4625049

Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

C Huggins, C V Hodges.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4625049     DOI： 10.3322/canjclin.22.4.232

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


× No keyword cloud information.
  270 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

2.  Androgen deprivation and thromboembolic events in men with prostate cancer.

Authors:  Behfar Ehdaie; Coral L Atoria; Amit Gupta; Andrew Feifer; William T Lowrance; Michael J Morris; Peter T Scardino; James A Eastham; Elena B Elkin
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

3.  Cardiac and cognitive effects of androgen deprivation therapy: are they real?

Authors:  S M H Alibhai; H Z Mohamedali
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

4.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

5.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

6.  Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.

Authors:  Takeshi Hashimoto; Krishnan Rahul; Toshikazu Takeda; Nicole Benfante; John P Mulhall; Hedvig Hricak; James A Eastham; Hebert Alberto Vargas
Journal:  Urol Oncol       Date:  2016-09-22       Impact factor: 3.498

7.  Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).

Authors:  Yasuhide Kitagawa; Satoru Ueno; Kouji Izumi; Atsushi Mizokami; Shiro Hinotsu; Hideyuki Akaza; Mikio Namiki
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-13       Impact factor: 4.553

8.  A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.

Authors:  Lauren Brady; Rui M Gil da Costa; Ilsa M Coleman; Clinton K Matson; Michael C Risk; Roger T Coleman; Peter S Nelson
Journal:  Prostate       Date:  2020-02-18       Impact factor: 4.104

9.  Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study.

Authors:  Cindy Ke Zhou; Alyson J Littman; Paul H Levine; Heather J Hoffman; Sean D Cleary; Emily White; Michael B Cook
Journal:  Prostate       Date:  2014-12-09       Impact factor: 4.104

10.  National practice patterns and time trends in androgen ablation for localized prostate cancer.

Authors:  Matthew R Cooperberg; Gary D Grossfeld; Deborah P Lubeck; Peter R Carroll
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.